Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 17-23, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christofides, N. D.
Right arrow Articles by Sheehan, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christofides, N. D.
Right arrow Articles by Sheehan, C. P.

Clinical Chemistry, Vol 41, 17-23, Copyright © 1995 by American Association for Clinical Chemistry

Enhanced chemiluminescence labeled-antibody immunoassay (Amerlite-MAB) for free thyroxine: design, development, and technical validation

ND Christofides and CP Sheehan
Cardiff Laboratories, Kodak Clinical Diagnostics Ltd., Amersham, UK.

We describe the development and validation of a one-step nonradioactive immunoassay for free thyroxine (Amerlite-MAB FT4) in serum or plasma, in the dedicated Amerlite enhanced luminescence assay system. A monoclonal antibody to thyroxine (T4), conjugated with horseradish peroxidase (HRP; EC 1.11.1.7), competes for binding with FT4 or with a conjugate of a protein and L-triiodothyronine immobilized onto the surface of the assay microwells. The signal is generated by antibody- HRP bound to the protein-T3 conjugate, with luminol as substrate. The assay design exploits the high sensitivity of luminescence signal detection, permitting minimal sample dilution and T4 sampling by the antibody. It withstands progressive dilution of serum and is unaffected by T4-binding proteins in serum. The disclosure and validation of this FT4 assay follows guidelines recommended by the American Thyroid Association.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. E.M. Midgley and N. D. Christofides
Point: Legitimate and Illegitimate Tests of Free-Analyte Assay Function
Clin. Chem., March 1, 2009; 55(3): 439 - 441.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Nagasaki, M. Inaba, Y. Kumeda, Y. Hiura, K. Shirakawa, S. Yamada, Y. Henmi, E. Ishimura, and Y. Nishizawa
Increased Pulse Wave Velocity in Subclinical Hypothyroidism
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 154 - 158.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. E.M. Midgley
Direct and Indirect Free Thyroxine Assay Methods: Theory and Practice
Clin. Chem., August 1, 2001; 47(8): 1353 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. D. Christofides, E. Wilkinson, M. Stoddart, D. C. Ray, and G. J. Beckett
Assessment of Serum Thyroxine Binding Capacity-dependent Biases in Free Thyroxine Assays
Clin. Chem., April 1, 1999; 45(4): 520 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
H. P. Stevenson, G. Pooler, R. Archbold, P. Johnston, I. S. Young, and B. Sheridan
Misleading serum free thyroxine results during low molecular weight heparin treatment
Clin. Chem., May 1, 1998; 44(5): 1002 - 1007.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.